Main Article Content
Background D-dimer is a molecule as result of breaking down
of excessive fibrin formation from the activation of coagulation
system. There is evidence of increased activation of coagulation in
patients with acute leukemia which was showed by the increment
of d-dimer levels.
Objective To evaluate the incidence of activation of coagulation
sys tem in children with acute leukemia before receiving
Method This cross-sectional study was performed at Dr. Cipto
Mangunkusumo Hospital. All newly-diagnosed children with acute
leukemia were included in this study, prior to their receiving any
chemotherapy treatment. Blast count, prothrombin time (PTI),
activated partial thromboplastin time (APTf), and D-dimer levels
were examined after the diagnosis was confirmed by morphology and
immunophenotyping studies on bone marrow specimens.
Results Out of 22 subjects, 13 subjects had increased D-dimer
values. The median D-dimer level of this elevated group was 1,000
(range 500-14, 700) n gfmL. In the acute myeloblastic leukemia
(AML) patients, activation of coagulation was found in 7 out of 8
subjects. The median D-dimer levels was 950 (range 100-14, 700)
ng/mL. In the acute lymphocytic leukemia (ALL) patients, 6 out
of 14 subjects had increased activation of coagulation with median
D-dimer level of 300 (range 100-3,800) ngfmL. Nine out of 10
subjects with blast cells on peripheral blood smear had a median
D-dimer level of 1,000 (range 500-3,800) ng/mL. Both PT and
APTT were found normal in all subjects.
Conclusion Activation of coagulation sys tem occurs at the
time of diagnosis as shown by increased D-dimer levels. The
characteristics of activation of coagulation system are different
between ALL and AML subjects, as well as between subj ects with
positive and negative blast counts on peripheral blood smears.
Despite the increased activation of coagulation, PT and APTf
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
2. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altamore M, et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. AmJ Hematol. 20 10;85:325-30.
3. Abshire TC, Gold SH, Odom LF, Carson SD, Hathaway WE. The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? Cancer. 1990;66:716-21.
4. Yanada M, Matsushita T, Suzuki M, Kiyoi H, Yamamoto K, Kinoshita T, et al. Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation. Eur J Haematol. 2006;77:282-7.
5. Ch ojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Ciemiewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma. 1999;36:77-84.
6. Nadir Y, Katz T, Sarig G, Hoffman R, Oliven A, Rowe JM, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematol. 2005;90:1549-56.
7. Albayrak M, Giirsel T, Kaya Z, Kascak U. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost. 2013;19:644-51.
8. Giordano P, Del Vecchio GC, Santoro N, Arcamone G, Coppola B, Altomare M, et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. Pediatr Hematol Oneal. 2000;17:667-72.
9. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003;111:199-212.
10. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008;34:204-10.
11. Merrell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994-1004.
12. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complication of cancer: epidemiology, pathogenesis, diagnosis and treatment. Am J Hematol. 2003;72:43-52.
13. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2012;156:24-36.
14. Bajzar L, Chan AK, Massicotte MP, Mitchell LG. Thrombosis in children with malignancy. Curr Opin Pediatr. 2006;18:l-9.
15. Falanga A, Russo L, and Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis [ serial on the internet]. 2011 December 21; [cited 2012 May 15] ; 3: [ about 12 screens]. Available from: http://www.mjhid.org/article/view/9626.
16. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res .2001; 102:215-24.
17. Donati MB, Lorenzet R. Coagulation factors and tumor cell biology: the role of tissue factor. Pathophysiol Haemost Thromb. 2003;33:22-5.
18. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood. 1988;71:870-5.
19. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92:143-51.
20. Totan M, Dagdemir A, Ak AR, Albayrak D, Kucukoduk S. Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 2001;36:429-33.
21. Fisgin T, Yarali N, Kara A, Bozkurt C, Birgen D, Erten U, et al. Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2004;2l:77-83.
22. Nowak-Gottl U, Ahlke E, Schulze,Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol. 1996;95:123-6.
23. Nowak-Gottl U, Ahlke E, Klose! K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr. 1997;156:848-50.
24. Nowak-Gottl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol. 1996;56:35-8.
25. Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100:330-7.
26. Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica. 1996;81:127-31.
27. Gatot D, Pringgardini K, Suradi R. Coagulation abnormality as a complication of L-asparaginase therapy in childhood acute lymphoblastic leukemia. Paediatr Indones. 2006;46:46-50.
28. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101:2529-33.
29. Goldschmidt B, Koos R. Metabolism of fibrinogen in children with acute lymphoblastic leukaemia. Eur J Pediatr. 1984;143:140-4.
30. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216-22.
31. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber cancer institute consortium protocols. Br J Haematol. 2011;152:452-9.
32. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508-16.
33. Al-Aridi C, Abboud MR, Saab R, Eid D,Jeha S, Chan AK,et al. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models. Pediatr Hematol Oncol. 2011;28:676-81.
34. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129:803-10.
35. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93:1595-9